PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:1402011
Landmark trials in Ovarian Cancer | PPT
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer | Journal of Clinical Oncology
Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
2020 ASCO Annual Meeting - Conference Program - Clin Onc 2020 - 22991 | CCO
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer | NEJM
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
PDF) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer - ScienceDirect
Shannon Westin, MD, MPH, FASCO on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent # ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" /
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer | Journal of Clinical Oncology
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option - ScienceDirect
Advances in ovarian cancer, from biology to treatment | Nature Cancer
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Targeted Therapy in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
ESGO on X: "👋 Ready for the next #ENYGO webinar? Register now for our webinar with Andreas du Bois. He'll talk about DESKTOP III Trial Results: Do patients in recurrent ovarian cancer
PPT - An Oncology Exchange Activity PowerPoint Presentation, free download - ID:5600388
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Table 4 from Surgical management of recurrent ovarian cancer. | Semantic Scholar
Epithelial ovarian cancer - The Lancet
JGO :: Journal of Gynecologic Oncology
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial - The Lancet Oncology
